T. Rowe Price Associates
CYTK icon

T. Rowe Price Associates’s Cytokinetics CYTK Stock Holding History

T. Rowe Price Associates’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167M Buy
1,958,946
+374,625
+24% +$26.9M 0.02% 557
2026
Q1 		$104M Sell
1,584,321
-345,798
-18% -$22M 0.01% 602
2025
Q4 		$123M Sell
1,930,119
-436,729
-18% -$27.2M 0.01% 588
2025
Q3 		$130M Buy
2,366,848
+500,871
+27% +$20.6M 0.01% 561
2025
Q2 		$61.7M Sell
1,865,977
-127,919
-6% -$4.45M 0.01% 680
2025
Q1 		$80.1M Sell
1,993,896
-631,185
-24% -$29M 0.01% 594
2024
Q4 		$123M Sell
2,625,081
-539,864
-17% -$28M 0.01% 528
2024
Q3 		$167M Buy
3,164,945
+806,602
+34% +$45M 0.02% 469
2024
Q2 		$128M Sell
2,358,343
-572,605
-20% -$34.6M 0.02% 493
2024
Q1 		$205M Sell
2,930,948
-313,302
-10% -$24.2M 0.03% 416
2023
Q4 		$271M Buy
3,244,250
+2,232,623
+221% +$80.8M 0.04% 358
2023
Q3 		$29.8M Sell
1,011,627
-73,686
-7% -$2.45M ﹤0.01% 822
2023
Q2 		$35.4M Sell
1,085,313
-86,716
-7% -$3.21M ﹤0.01% 800
2023
Q1 		$41.2M Buy
1,172,029
+64,168
+6% +$2.62M 0.01% 733
2022
Q4 		$50.8M Buy
1,107,861
+14,414
+1% +$620K 0.01% 657
2022
Q3 		$53M Buy
1,093,447
+595,708
+120% +$28.7M 0.01% 631
2022
Q2 		$19.6M Buy
497,739
+35,256
+8% +$1.42M ﹤0.01% 1169
2022
Q1 		$17M Buy
462,483
+313,044
+209% +$11.1M ﹤0.01% 1269
2021
Q4 		$6.81M Buy
149,439
+119,982
+407% +$4.63M ﹤0.01% 1462
2021
Q3 		$1.05M Buy
29,457
+1,016
+4% +$29.9K ﹤0.01% 2040
2021
Q2 		$563K Buy
28,441
+1,261
+5% +$29.6K ﹤0.01% 2335
2021
Q1 		$632K Buy
27,180
+3,654
+16% +$78K ﹤0.01% 2252
2020
Q4 		$489K Sell
23,526
-636,628
-96% -$11.6M ﹤0.01% 2248
2020
Q3 		$14.3M Buy
+660,154
New +$15.4M ﹤0.01% 1219
2018
Q1 		– Sell
-427,148
Closed -$3.48M – 2559
2017
Q4 		$3.48M Buy
427,148
+1,890
+0.4% +$21.5K ﹤0.01% 1473
2017
Q3 		$6.17M Buy
+425,258
New +$5.81M ﹤0.01% 1410
2013
Q4 		– Sell
-1,431,573
Closed -$10.9M – 2491
2013
Q3 		$10.9M Sell
1,431,573
-42,285
-3% -$454K ﹤0.01% 1250
2013
Q2 		$17.1M Buy
+1,473,858
New +$11.6M ﹤0.01% 1111

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's CYTK Position: Q2 2026 in Review

T. Rowe Price Associates increased its Cytokinetics (CYTK) stake by 24% in Q2 2026, buying an estimated $26.9M and bringing the position to 1,958,946 shares worth $167M. The position accounts for 0.02% of the portfolio, ranked #557.

T. Rowe Price Associates first reported a position in CYTK in Q2 2013 and has held it in 28 quarters since. The position peaked at $271M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • T. Rowe Price Associates held 1,958,946 shares of Cytokinetics worth $167M as of Q2 2026.
  • T. Rowe Price Associates bought 374,625 Cytokinetics shares in Q2 2026, an estimated $26.9M.
  • Cytokinetics made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #557 holding.
  • T. Rowe Price Associates first reported a position in Cytokinetics in Q2 2013 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Cytokinetics position peaked at $271M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.